Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PITPNM2 antisense RNA 1 (PITPNM2-AS1)
- Target
- PITPNM2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
PITPNM2 antisense RNA 1 (PITPNM2-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the PITPNM2 gene. It is classified as an antisense RNA and is not a protein or receptor; rather, it regulates gene expression post-transcriptionally. PITPNM2-AS1 is reported to be overexpressed in non-small cell lung cancer (NSCLC) tissues and cell lines, where it promotes cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT), in part by acting as a molecular sponge for microRNA-32-5p. Silencing PITPNM2-AS1 suppresses these oncogenic properties, suggesting a role as a potential diagnostic and prognostic cancer biomarker. No clinically approved drugs target PITPNM2-AS1 directly.
- Other names
- PITPNM2-AS1
02
Mechanism of action
Acts as a competing endogenous RNA (ceRNA) by sponging microRNA-32-5p; modulates downstream signaling relevant to proliferation, migration, and EMT
03
Biological functions
Regulation of gene expressionRegulation of cell proliferationModulation of epithelial-mesenchymal transition (EMT)Regulation of cell migration and invasion
04
Disease associations
Cancer, particularly non-small cell lung cancer (NSCLC)possibly implicated in other cancers, though not definitively established
05
Safety considerations
Not established; as a non-coding RNA, safety concerns are primarily theoretical or experimental and not clinically described
06
Biomarkers
Potential diagnostic and prognostic biomarker for non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on PITPNM2 antisense RNA 1 (PITPNM2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PITPNM2 antisense RNA 1 (PITPNM2-AS1).